Clinical Investigation Facility, David Grant USAF Medical Center, 101 Bodin Circle, Travis Air Force Base, CA 94533, USA; Division of Emergency Medicine, University of Utah Health, 30N 1900 E, Salt Lake City, UT 84132, USA.
Clinical Investigation Facility, David Grant USAF Medical Center, 101 Bodin Circle, Travis Air Force Base, CA 94533, USA; Department of Surgery, University of California Davis Medical Center, 2315 Stockton Blvd, Sacramento, CA 95817, USA.
Injury. 2020 Oct;51(10):2165-2171. doi: 10.1016/j.injury.2020.07.005. Epub 2020 Jul 3.
Resuscitative endovascular balloon occlusion of the aorta (REBOA) causes myocardial injury from increased aortic afterload and supraphysiologic cardiac output. However, pharmacologic methods to attenuate high cardiac output and reduce myocardial injury have not been explored. We hypothesized that the use of esmolol during REBOA would reduce myocardial injury.
Ten pigs were anesthetized and instrumented. Following 25% total blood volume hemorrhage, animals underwent 45 min of supraceliac (zone 1) REBOA with or without titration of esmolol to maintain heart rate between 80 and 100 beats per minute. Following the REBOA interventions, animals underwent 275 min of standardized critical care.
During REBOA, heart rate was significantly lower in the esmolol group compared to control animals (100 [88 - 112] vs 193 [172 - 203] beats/minute, respectively, p < 0.001) and the average mean arterial pressure (MAP) was lower in the esmolol group (88.0 [80.3-94.9] vs 135.1 [131.7-140.4] mmHg, respectively, p = 0.01). During the critical care phase, there were no differences in heart rate or MAP between groups. Animals in the intervention group received 237.9 [218.7-266.5] µg/kg of esmolol. There was a significant increase from baseline in serum troponins for the control group (p = 0.006) and significantly more subendocardial hemorrhage compared to animals treated with esmolol (3 [3 - 3] and 0 [0 - 0], p = 0.009, respectively).
In our porcine model of hemorrhagic shock, zone 1 REBOA was associated with myocardial injury. Pharmacologic heart rate titration with esmolol during occlusion may mitigate the deleterious effects of REBOA on the heart.
主动脉球囊阻断复灌(REBOA)会增加主动脉后负荷和高于生理的心输出量,从而导致心肌损伤。然而,尚未探索减轻高心输出量和减少心肌损伤的药理学方法。我们假设在 REBOA 期间使用艾司洛尔会减少心肌损伤。
10 头猪被麻醉并进行了仪器操作。在经历 25%全血容量失血后,动物经历了 45 分钟的 supra 腹主动脉(区域 1)REBOA,并用艾司洛尔滴定以维持心率在 80 至 100 次/分钟之间。在 REBOA 干预后,动物接受了 275 分钟的标准化重症监护。
在 REBOA 期间,艾司洛尔组的心率明显低于对照组(分别为 100[88-112]和 193[172-203]次/分钟,p<0.001),平均平均动脉压(MAP)也较低(分别为 88.0[80.3-94.9]和 135.1[131.7-140.4]mmHg,p=0.01)。在重症监护阶段,两组之间的心率或 MAP 没有差异。干预组的动物接受了 237.9[218.7-266.5]µg/kg 的艾司洛尔。与接受艾司洛尔治疗的动物相比,对照组的血清肌钙蛋白基线显著增加(p=0.006),并且心内膜下出血明显更多(分别为 3[3-3]和 0[0-0],p=0.009)。
在我们的失血性休克猪模型中,区域 1 REBOA 与心肌损伤有关。在阻断期间用艾司洛尔进行药理学心率滴定可能会减轻 REBOA 对心脏的有害影响。